{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:43:02Z","timestamp":1792546982083,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd013306","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T00:00:00Z","timestamp":1613952000000}}],"reference-count":91,"publisher":"Wiley","issue":"2","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013306.pub2","type":"journal-article","created":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T11:27:17Z","timestamp":1615462037000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":98,"title":["Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis"],"prefix":"10.1002","volume":"2021","author":[{"given":"Ceri E","family":"Battle","sequence":"additional","affiliation":[{"name":"Welsh Centre for Emergency Medicine Research; ABM University Health Board; Swansea UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azmil H","family":"Abdul-Rahim","sequence":"additional","affiliation":[{"name":"Institute of Neuroscience and Psychology; University of Glasgow; Glasgow UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan D","family":"Shenkin","sequence":"additional","affiliation":[{"name":"Geriatric Medicine, Usher Institute; University of Edinburgh; Edinburgh UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Hewitt","sequence":"additional","affiliation":[{"name":"3rd Floor, Academic Building, Llandough Hospital.; Cardiff University and Aneurin Bevan Health Board; Cardiff UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry J","family":"Quinn","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular and Medical Sciences; University of Glasgow; Glasgow UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,2,22]]},"reference":[{"key":"10.1002\/14651858.CD013306.pub2-BIB0001|cit1","unstructured":"Auchus A A randomized, 26-week, double-blind, placebo-controlled trial to evaluate the safety and efficacy of galantamine in the treatment of dementia secondary to cerebrovascular disease IFPMA register 2004 1 1 3"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1212\/01.wnl.0000266625.31615.f6","article-title":"Galantamine treatment of vascular dementia: a randomised trial","volume":"69","author":"Auchus","year":"2007","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0003|cit3","unstructured":"A placebo controlled trial to evaluate the safety and efficacy of galantamine in the treatment of vascular dementia https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00035191"},{"issue":"9","key":"10.1002\/14651858.CD013306.pub2-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1185\/03007990802328142","article-title":"Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the Vantage study","volume":"24","author":"Ballard","year":"2008","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1161\/01.STR.0000091396.95360.E1","article-title":"Efficacy and tolerability of Donepezil in vascular dementia: positive results of a 24-week, multi-centre, international, randomised, placebo-controlled trial","volume":"34","author":"Black","year":"2003","journal-title":"Stroke"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0197-4580(04)81550-1","article-title":"Vascular dementia patients who receive Donepezil treatment for 12 to 18 months maintain cognitive benefits","volume":"25","author":"Doody","year":"2004","journal-title":"Neurobiology of Aging"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0007|cit7","first-page":"35","article-title":"Donepezil slows functional deterioration in patients with vascular dementia","volume":"9","author":"Geldmacher","year":"2002","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0022-510X(02)00266-6","article-title":"Patient populations in clinical trials of the efficacy and tolerability of donepezil in patients with vascular dementia","volume":"203","author":"Pratt","year":"2002","journal-title":"Journal of the Neurological Sciences"},{"issue":"1 Suppl S57","key":"10.1002\/14651858.CD013306.pub2-BIB0009|cit9","first-page":"S57","article-title":"Donepezil is well tolerated in patients with vascular dementia: a comparison of safety and tolerability results from randomized, placebo-controlled clinical trials in vascular dementia patients and Alzheimer's disease patients","volume":"23","author":"Pratt","year":"2002","journal-title":"Neurobiology of Aging"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0010|cit10","unstructured":"Pratt RD Perdomo CA The Donepezil 307 VaD Study Group Population characteristics and pattern of cognitive decline in patients with vascular dementia enrolled in two 24-week, randomized, double-blind, placebo-controlled trials 7th International Geneva\/Springfield Symposium on Advances in Alzheimer therapy; 2002 Apr 03-06; Geneva 2002"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1749-6632.2002.tb04859.x","article-title":"Donepezil-treated patients with probable vascular dementia demonstrate cognitive benefits","volume":"977","author":"Pratt","year":"2002","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"S481","DOI":"10.1016\/S0924-977X(06)70642-3","article-title":"Efficacy and safety of donepezil in vascular dementia: results from the largest double-blind trial in vascular dementia patients","volume":"16","author":"Roman","year":"2006","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0013|cit13","unstructured":"Roman GC Pratt RD Perdomo CA The Donepezil Study Group Donepezil improves cognition in patients with vascular dementia: results from Study 307, a 24-week randomized, double-blind, placebo-controlled trial 8th International Conference on Alzheimer's Disease and Related Disorders; 2002 Jul 20-25, Stockholm 2002"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0014|cit14","unstructured":"Schindler R Perdomo CA Pratt RD Donepezil provides significant benefits to patients with vascular dementia in their ability to perform everyday activities 8th Congress of the European Federation of the Neurological Sciences; 2004 Sep 04-07; Paris 2004"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S0197-4580(04)81551-3","article-title":"Donepezil provides significant benefits to patients with vascular dementia in their ability to perform everyday activities","volume":"25","author":"Seltzer","year":"2004","journal-title":"Neurobiology of Aging"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000074140","article-title":"Management of patients with Alzheimer's disease plus cerebrovascular disease: 12-month treatment with galantamine","volume":"17","author":"Bullock","year":"2004","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0017|cit17","unstructured":"Burke W Lilienfeld S Galantamine improves behaviour and relieves caregiver distress in Alzheimer's disease (AD), vascular dementia and AD with cerebrovascular disease 8th international conference on Alzheimer's disease and related disorders; 2002 Jul 20-25; Stockholm 2002"},{"issue":"7","key":"10.1002\/14651858.CD013306.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1177\/0269881107083028","article-title":"Galantamine treatment in Alzheimer's disease with cerebrovascular disease: responder analyses from a randomized, controlled trial (GAL-INT-6)","volume":"22","author":"Erkinjuntti","year":"2008","journal-title":"Journal of Psychopharmacology"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S0140-6736(02)08267-3","article-title":"Efficacy of Galantamine in probable vascular dementia and Alzheimer's disease combined with cardiovascular disease: a randomised trial","volume":"359","author":"Erkinjuntti","year":"2002","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0149-2918(03)80168-6","article-title":"An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia","volume":"25","author":"Erkinjuntti","year":"2003","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0021|cit21","unstructured":"Erkinjuntti T Lilienfeld S Damaraju CV Long-term treatment with galantamine is effective in slowing cognitive decline in patients with probable vascular dementia 7th International Geneva\/Springfield Symposium on Advances in Alzheimer Therapy; 2002 Apr 03-06; Geneva 2002"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1046\/j.1468-1331.2002.04455.x","article-title":"Broad therapeutic benefits in patients with probable vascular dementia or Alzheimer's disease with cerebrovascular disease after treatment with galantamine","volume":"9","author":"Erkinjuntti","year":"2002","journal-title":"European Journal of Neurology"},{"issue":"6","key":"10.1002\/14651858.CD013306.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s11910-002-0036-z","article-title":"Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial","volume":"2","author":"Kertesz","year":"2002","journal-title":"Current Neurology and Neuroscience Reports"},{"issue":"6","key":"10.1002\/14651858.CD013306.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s11910-002-0036-z","article-title":"Galantamine in vascular dementia and Alzheimer's disease combined with cerebrovascular disease","volume":"2","author":"Kertesz","year":"2002","journal-title":"Current Neurology and Neuroscience Reports"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0025|cit25","first-page":"273","article-title":"Long-term safety, tolerability, and efficacy of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease: an interim analysis","volume":"11","author":"Kurz","year":"2003","journal-title":"International Psychogeriatrics"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0026|cit26","unstructured":"Kurz A Lilienfeld S Damaraju CV Galantamine is safe and effective for the long-term treatment of cognitive decline in patients with Alzheimer disease with cerebrovascular components or probable vascular dementia 7th International Geneva\/Springfield Symposium on Advances in Alzheimer therapy; 2002 Apr 03-06; Geneva 2002"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1034\/j.1600-0404.106.s178.5.x","article-title":"Non-cognitive benefits of galantamine (Reminyl(R)) treatment in vascular dementia","volume":"106","author":"Kurz","year":"2002","journal-title":"Acta Neurologica Scandinavica"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1046\/j.1468-1331.2003.00677.x","article-title":"Long-term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease","volume":"10","author":"Kurz","year":"2003","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2165\/00023210-200317120-00004","article-title":"Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease","volume":"17","author":"Small","year":"2003","journal-title":"CNS Drugs"},{"issue":"6","key":"10.1002\/14651858.CD013306.pub2-BIB0030|cit30","first-page":"943","article-title":"Rivastigmine in Chinese patients with subcortical vascular dementia","volume":"3","author":"Mok","year":"2007","journal-title":"Neuropsychiatric Disease and Treatment"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1600-0404.2009.01263.x","article-title":"A randomised controlled trial of Rivastigmine in patients with cognitive impairment no dementia because of cerebrovascular disease","volume":"121","author":"Narasimhalu","year":"2010","journal-title":"Acta Neurologica Scandinavica"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0032|cit32","unstructured":"Pratt RD Perdomo CA Donepezil improves cognitive function in patients with vascular dementia: results from study 307, a 24-week, randomized, double-blind, placebo-controlled trial Portal of Geriatrics Online Education 2002 7 A161 2"},{"issue":"6","key":"10.1002\/14651858.CD013306.pub2-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1161\/STROKEAHA.109.570077","article-title":"Randomised, placebo-controlled, clinical trial of Donepezil in vascular dementia","volume":"41","author":"Roman","year":"2010","journal-title":"Stroke"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0034|cit34","unstructured":"Aguilar M Roman G Black S Royall D Surick I Kumar D Efficacy and safety of donepezil in vascular dementia results from largest double-blind trial in vascular dementia patients 10th International Conference on Alzheimer's Disease and Related Disorders; 2006 Jul 15-20; Madrid 2006"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0035|cit35","unstructured":"Bayer A Pratt RD Kumar D A comparison of the cognitive benefits of donepezil in patients with cortical and subcortical vascular dementia 8th Congress of the European Federation of the Neurological Sciences; 2004 Sep 04-07; Paris 2004"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0036|cit36","first-page":"A46","article-title":"Donepezil provides significant benefits in patients with vascular dementia","volume":"33","author":"Boundy","year":"2003","journal-title":"Internal Medicine Journal"},{"issue":"4","key":"10.1002\/14651858.CD013306.pub2-BIB0037|cit37","first-page":"429","article-title":"Efficacy of donepezil in vascular dementia","volume":"61","author":"Farlow","year":"2003","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0038|cit38","first-page":"S57","article-title":"Donepezil is well tolerated in patients with vascular dementia: a comparison of safety and tolerability results from randomized, placebo-controlled clinical trials in vascular dementia patients and Alzheimer's disease patients","volume":"1","author":"Pratt","year":"2002","journal-title":"Neurobiology of Aging"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0039|cit39","unstructured":"Pratt RD Perdomo CA The Donepezil 308 VaD Study Group Cognitive and global benefits of donepezil in vascular dementia: results from study 308, a 24-week, randomized, double-blind, placebo-controlled trial 7th International Geneva\/Springfield Symposium on Advances in Alzheimer therapy; 2002 Apr 03-06; Geneva 2002"},{"issue":"6","key":"10.1002\/14651858.CD013306.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000088494","article-title":"Donepezil in vascular dementia: combined analysis of two large-scale clinical trials","volume":"20","author":"Roman","year":"2005","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0041|cit41","first-page":"57","article-title":"Donepezil-treated patients with vascular dementia demonstrate cognitive and global benefits: results from study 308, a 24-week, randomized, double-blind, placebo-controlled trial","volume":"1","author":"Salloway","year":"2002","journal-title":"Neurobiology of Aging"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0042|cit42","first-page":"165","article-title":"Donepezil is well tolerated in patients with vascular dementia: a comparison of tolerability in vascular dementia patients and Alzheimer's disease patients","volume":"9","author":"Salloway","year":"2002","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1212\/01.WNL.0000078943.50032.FC","article-title":"Donepezil in vascular dementia: a randomised, placebo-controlled study","volume":"61","author":"Wilkinson","year":"2003","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/gps.2340","article-title":"The long-term efficacy and tolerability of donepezil in patients with vascular dementia","volume":"25","author":"Wilkinson","year":"2010","journal-title":"Int J Geriat Psychiatry"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S1474-4422(08)70046-2","article-title":"Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL","volume":"7","author":"Dichgans","year":"2008","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0046|cit46","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013"},{"issue":"1","key":"10.1002\/14651858.CD013306.pub2-BIB0047|cit47","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005593","article-title":"Cholinesterase inhibitors for Alzheimer's disease","author":"Birks","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD013306.pub2-BIB0048|cit48","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004744.pub3","article-title":"Rivastigmine for vascular cognitive impairment","author":"Birks","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1159\/000444253","article-title":"Efficacy of cholinesterase inhibitors in vascular dementia: an updated meta-analysis","volume":"75","author":"Chen","year":"2016","journal-title":"European Neurology"},{"issue":"3","key":"10.1002\/14651858.CD013306.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2174\/1570159X11311030006","article-title":"Acetylcholinesterase inhibitors: pharmacology and toxicology","volume":"11","author":"Colovi\u0107","year":"2013","journal-title":"Current Neuropharmacy"},{"issue":"1","key":"10.1002\/14651858.CD013306.pub2-BIB0051|cit51","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004746.pub2","article-title":"Galantamine for vascular cognitive impairment","author":"Craig","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0052|cit52","volume-title":"Neurobiology of Alzheimer\u2019s Disease","author":"Dawbarn","year":"2001"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1161\/CIRCRESAHA.116.308426","article-title":"Vascular cognitive impairment","volume":"120","author":"Dichgans","year":"2017","journal-title":"Circulation Research"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1161\/01.STR.0000120731.88236.33","article-title":"Emerging therapies for vascular dementia and vascular cognitive impairment","volume":"35","author":"Erkinjuntti","year":"2004","journal-title":"Stroke"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0055|cit55","unstructured":"McMaster University (developed by Evidence Prime) GRADEpro GDT 2008"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0056|cit56","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017 Available from training.cochrane.org\/handbook\/archive\/v5.2"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/j.1468-1331.2010.03040.x","article-title":"EFNS guidelines for the diagnosis and management of Alzheimer\u2019s disease","volume":"17","author":"Hort","year":"2010","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1002\/sim.6188","article-title":"A design-by-treatment interaction model for network meta-analysis with random inconsistency effects","volume":"33","author":"Jackson","year":"2014","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S1474-4422(07)70195-3","article-title":"Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials","volume":"6","author":"Kavirajan","year":"2007","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0060|cit60","doi-asserted-by":"publisher","first-page":"451","DOI":"10.2147\/CLEP.S69660","article-title":"Bias in identification of the best treatment in a Bayesian network meta-analysis for binary outcome: a simulation study","volume":"6","author":"Kibret","year":"2014","journal-title":"Clinical Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD013306.pub2-BIB0061|cit61","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009444.pub3","article-title":"Cholinesterase inhibitors for rarer dementias associated with neurological conditions","author":"Li","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1527-3458.2002.tb00221.x","article-title":"Galantamine: a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer\u2019s disease","volume":"8","author":"Lilienfeld","year":"2002","journal-title":"CNS Drug Reviews"},{"issue":"1","key":"10.1002\/14651858.CD013306.pub2-BIB0063|cit63","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004395.pub2","article-title":"Donepezil for vascular cognitive impairment","author":"Malouf","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD013306.pub2-BIB0064|cit64","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1159\/000350800","article-title":"Diagnostic validity of the Alzheimer\u2019s Disease Functional Assessment and Change Scale in mild cognitive impairment and mild to moderate Alzheimer\u2019s disease","volume":"37","author":"Manero","year":"2013","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"issue":"4","key":"10.1002\/14651858.CD013306.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/jrsm.1287","article-title":"Machine Learning for Identifying Randomized Controlled Trials: an evaluation and practitioner\u2019s guide","volume":"9","author":"Marshall","year":"2018","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0066|cit66","unstructured":"McDonald S Noel-Storr AH Thomas J Harnessing the efficiencies of machine learning and Cochrane Crowd to identify randomised trials for individual Cochrane reviews Global Evidence Summit; 2017 Sep 13-16; Cape Town 2017"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0067|cit67","doi-asserted-by":"publisher","first-page":"f2914","DOI":"10.1136\/bmj.f2914","article-title":"Demystifying trial networks and network meta-analysis","volume":"346","author":"Mills","year":"2013","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0068|cit68","unstructured":"National Institute for Health and Care Excellence NICE guidelines: donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease. Technology appraisal guidance [TA217] www.nice.org.uk\/guidance\/ta217"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0069|cit69","unstructured":"Noel-Storr AH Project Transform Team Cochrane Crowd: new ways of working together to produce health evidence Evidence Live; 2018 Jun 18-20; Oxford 2018"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1474-4422(03)00305-3","article-title":"Vascular cognitive impairment","volume":"2","author":"O\u2019Brien","year":"2003","journal-title":"Lancet Neurology"},{"issue":"4","key":"10.1002\/14651858.CD013306.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/jrsm.1373","article-title":"MetaInsight: an interactive web-based tool for analyzing, interrogating, and visualizing network meta-analyses using R-shiny and netmeta","volume":"10","author":"Owen","year":"2019","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0072|cit72","first-page":"201","article-title":"Some developments in brain ageing and dementia","volume":"54","author":"Perry","year":"1997","journal-title":"British Journal of Biomedical Science"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"g5630","DOI":"10.1136\/bmj.g5630","article-title":"A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis","volume":"349","author":"Puhan","year":"2014","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"111","DOI":"10.31887\/DCNS.2009.11.2\/cqiu","article-title":"Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention","volume":"11","author":"Qiu","year":"2009","journal-title":"Dialogues in Clinical Neuroscience"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0075|cit75","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0076|cit76","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s11940-015-0367-0","article-title":"Treatment of vascular cognitive impairment","volume":"17","author":"Ritter","year":"2015","journal-title":"Current Treatment Options in Neurology"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/WNL.43.2.250","article-title":"Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop","volume":"43","author":"Roman","year":"1993","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0078|cit78","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Medical Research Methodology"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jrsm.1037","article-title":"Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool","volume":"3","author":"Salanti","year":"2012","journal-title":"Research Synthesis Methods"},{"issue":"2","key":"10.1002\/14651858.CD013306.pub2-BIB0081|cit81","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1136\/jnnp-2011-300881","article-title":"What is the clinically relevant change on the ADAS-Cog?","volume":"83","author":"Schrag","year":"2012","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0082|cit82","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JP Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and \u2018Summary of findings\u2019 tables. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.jalz.2016.10.007","article-title":"The Vascular Impairment of Cognition Classification Consensus Study","volume":"13","author":"Skrobot","year":"2017","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jclinepi.2017.08.011","article-title":"Living Systematic Review Network. Living Systematic Reviews: 2. Combining Human and Machine Effort","volume":"91","author":"Thomas","year":"2017","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/BF01271206","article-title":"Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarcts types as compared with Alzheimer-type dementia","volume":"103","author":"Toghi","year":"1996","journal-title":"Journal of Neural Transmission"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/ije\/dys041","article-title":"Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews","volume":"41","author":"Turner","year":"2012","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"18003","DOI":"10.1038\/nrdp.2018.3","article-title":"Vascular cognitive impairment","volume":"15","author":"Flier","year":"2018","journal-title":"Nature Reviews Disease Primers"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/ije\/dys222","article-title":"Evaluation of inconsistency in networks of interventions","volume":"42","author":"Veroniki","year":"2013","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0089|cit89","volume-title":"The ICD-11 Classification of Mental and Behavioural Disorders: Clinical Description and Diagnostic Guidelines","author":"World Health Organization","year":"1992"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0090|cit90","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/alzrt143","article-title":"Dementia: a global health priority - highlights from an ADI and World Health Organization report","volume":"4","author":"Wortmann","year":"2012","journal-title":"Alzheimer's Research & Therapy"},{"key":"10.1002\/14651858.CD013306.pub2-BIB0091|cit91","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/S1474-4422(15)00092-7","article-title":"Dementia in western Europe: epidemiological evidence and implications for policy making","volume":"15","author":"Wu","year":"2016","journal-title":"Lancet Neurology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T11:48:46Z","timestamp":1629978526000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013306.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Dementia and Cognitive Improvement Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,2,22]]},"references-count":91,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013306.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,22]]}}}